PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 83
• 4 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with muscle invasive bladder cancer or localized or locally advanced kidney cancer (renal cell cancer). It tests the safety of the E-VIM vaccine CVX1, with or without an immune checkpoint inhibitor (ICI).

Age

18 years or older

Sex

All sexes can join

Disease stage

Muscle invasive bladder cancer, or localized or locally advanced renal cell cancer (RCC)

Read by machine on 9 Nov 2026.

Sites (4)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details